Theravance Biopharma, Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for TBPH, updated each market day.
TBPH AI Sentiment
AI predicts Theravance Biopharma, Inc. stock is likely to decrease over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Theravance Biopharma, Inc.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
Sector
Exchange
Market Cap
$852,207,892
Cap Tier
Employees
90
Headquarters
GEORGE TOWN, GRAND CAYMAN, CA
Listed Since
May 16, 2014
Website
TBPH Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
TBPH Volatility
Theravance Biopharma, Inc. has shown moderate price volatility over the last 5 trading days. Moderate volatility indicates normal market activity with typical price fluctuations.
